Stay updated on Alvocidib Biomarker AML Phase 2 Clinical Trial
Sign up to get notified when there's something new on the Alvocidib Biomarker AML Phase 2 Clinical Trial page.

Latest updates to the Alvocidib Biomarker AML Phase 2 Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Revision: v3.4.2; removed the lapse-in-funding notice and Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check21 days agoChange DetectedA government funding/status notice was added and the page revision updated to v3.4.1 (replacing v3.4.0).SummaryDifference0.3%

- Check28 days agoChange DetectedAdded a glossary toggle and minor typography changes (e.g., capitalization and version string) that do not affect study content or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check64 days agoChange DetectedThe page's Locations section has been reorganized and expanded to include Ontario, Malaga, and Wales, replacing multiple location blocks. The Revision has been updated to v3.3.3.SummaryDifference2%

- Check85 days agoChange DetectedPage revision updated from v3.3.1 to v3.3.2.SummaryDifference0.0%

Stay in the know with updates to Alvocidib Biomarker AML Phase 2 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Alvocidib Biomarker AML Phase 2 Clinical Trial page.